Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by ...

Last week saw the newest third-quarter earnings release from Neuronetics, Inc. (NASDAQ:STIM), an important milestone in the company's journey to build a stronger business. Neuronetics reported ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today ...

Every investor in Neuronetics, Inc. (NASDAQ:STIM) should be aware of the most powerful shareholder groups. With 35% stake, individual investors possess the maximum shares in the company. In other ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

"Guidance... remains unchanged" with "total revenue between $160 million and $166 million," "gross margins... between 47% and 49%," "operating expenses in the range ...

Additionally, Neuronetics announced Dan Reuvers as its new chief executive officer and highlighted that the second quarter was operationally cash flow positive. These developments reflect ongoing ...

We recently compiled a list of the 10 Hot Penny Stocks to Buy Now. In this article, we are going to take a look at where Neuronetics, Inc. (NASDAQ:STIM) stands against the other hot penny stocks. On ...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% ...

Neuronetics also remains eligible for an additional $5 million of Tranche 2 funding, subject to certain customary conditions described in the agreement. The $2 million minimum liquidity requirement ...